PDS Biotech Clinical Update and Financial Results by Mark Eisenberg 27.03.2024 Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
Vaccinex Expands Access to ActivMAb Antigen Virus Technology by Lilu Anderson 21.02.2024 ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...
NEST Center: Biotech’s Big Leap by Lilu Anderson 13.02.2024 The Northeast Science and Technology Center in New Jersey is transforming into a major biotech hub through a strategic partnership. ...
BioVaxys Acquires IMV’s Immunotherapy Tech for Growth by John Darbie 13.02.2024 BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
Researchers from Cleveland Clinic and IBM Unveil AI Strategy for Immunotherapy Targets by Lilu Anderson 23.01.2024 Cleveland Clinic and IBM join forces to advance immunotherapy research through AI, unlocking new targets for cancer therapy. #Immunotherapy #AI ...